Full Text View
Tabular View
No Study Results Posted
Related Studies
Neuroprotection With Riluzole Patients With Early Multiple Sclerosis
This study is ongoing, but not recruiting participants.
Study NCT00501943   Information provided by University of California, San Francisco

First Received on July 12, 2007.   Last Updated on June 12, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Multiple Sclerosis
Additional conditions recognized in this trial
Sclerosis
More general conditions related to this trial
Autoimmune Diseases
Autoimmune Diseases of the Nervous System
Demyelinating Autoimmune Diseases, CNS
Demyelinating Diseases
Immune System Diseases
Nervous System Diseases
Pathologic Processes
Interventions listed in this trial
Riluzole/Placebo +Avonex
Additional drug interventions recognized in this trial
Interferon beta 1a
Riluzole
More general drug interventions related to this trial
Adjuvants, Immunologic
Anticonvulsants
Antineoplastic Agents
Central Nervous System Agents
Excitatory Amino Acid Agents
Excitatory Amino Acid Antagonists
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Neuroprotective Agents
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protective Agents
Therapeutic Uses
Sponsors listed in this trial
University of California, San Francisco
National Multiple Sclerosis Society
Oregon Health and Science University


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services